Finland· FI-REL-REL62071
ELAHERE
A mirvetuximab soravtansine product containing mirvetuximab soravtansine, registered in Finland by AbbVie Deutschland GmbH&Co.KG. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Mirvetuximab soravtansine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Mirvetuximab soravtansine · ATC L01FX26
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Mirvetuximab soravtansine
- Manufacturer
- AbbVie Deutschland GmbH&Co.KG
- Country
- Finland (FI)
- ATC code
- L01FX26
- ATC class
- Mirvetuximab soravtansine
- Defined daily dose
- 18 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirvetuximab soravtansine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElahere 5 mg/mlAbbVie Deutschland
- CzechiaELAHEREAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- IrelandELAHERE 5 mg/mL concentrate for solution for infusionImmunogen Biopharma (Ireland) Limited
- IcelandELAHEREAbbVie Deutschland GmbH & Co. KG
- NorwayElahereAbbVie Deutschland GmbH & Co
- PolandElahereAbbVie Deutschland GmbH & Co. KG
- SwedenELAHERE 5 mg/ml Koncentrat till infusionsvätska, lösningAbbVie Deutschland GmbH & Co KG
- SwitzerlandElahere
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Elahere
- Iceland · Elahere
- Liechtenstein · Elahere
- Norway · Elahere
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed332d6a-25b1-423d-a35a-594d7e66f46f GET /v1/drugs/ed332d6a-25b1-423d-a35a-594d7e66f46f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "5 mg/ml",
"atc_label": "mirvetuksimabi-soravtansiini",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1866/001",
"fimea_rel_id": "REL62071",
"authorised_at": "2024-11-14"
}See everything about mirvetuximab soravtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.